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Abstract
Acne vulgaris is a multifactorial disorder of the pilosebaceous unit. The clinical picture 
can range from mild comedones to fulminant, scarring cases. Approximately 83–100% of 
all adolescents experience acne vulgaris at some point of their lives. Although acne often 
tends to resolve following the adolescent period, many men and women continue to suf-
fer from either active acne or postinflammatory scars into their twenties and thirties. Most 
patients with acne vulgaris are in the complicated adolescence period and thus carry 
a distinctive psychosocial burden. They possess a disease stigma on their skin for the 
external world to criticize every day. For all these reasons, acne is a disease which should 
be treated promptly and efficiently in all age groups. This chapter will provide a com-
prehensive and up-to-date review of pathophysiology of acne vulgaris, new molecular 
mechanisms on the evolving acne lesions, epidemiology of the disease, and latest treat-
ment options. The molecular biology of acne lesions, novel treatment options including 
cosmetic approaches, their role in acne pathogenesis, pathophysiology, and mechanism 
of actions of the drugs, safety, and efficacy issues, and various treatment regimens will 
be discussed along with novel discoveries and areas in which further research is needed.
Keywords: acne vulgaris, acne vulgaris pathophysiology, treatment of acne vulgaris, 
systemic treatment of acne vulgaris
1. Introduction
Acne vulgaris is a disease of the pilosebaceous unit. The disorder has a very broad spectrum 
of clinical picture, from mild comedones to deep inflamed nodules with systemic findings. 
Acne vulgaris is mainly observed during the adolescent period. Although all age groups may 
be affected, being primarily a disorder of adolescence, it has a big psychosocial effect leading 
to low self-esteem, social isolation, and major depression [1].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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distribution, and reproduction in any medium, provided the original work is properly cited.
2. History
The source of the word acne is controversial. It may be derived from the Greek achne, a word 
meaning efflorescence, or the Greek acme (Latin acme), which implies a summit or peak. 
Others have pointed to a hieroglyphic for the word AKU-T as the first written record refer-
ring to acne, a symbol interpreted to mean “boils,” “pustules,” or “a painful swelling” [2]. In 
the sixth century AD, the term “acne” was first used by the Emperor Justinian’s physician, 
Aetius Amidenus [3]. Its use became obsolete by the 1800s, when “acne” regained a place in 
medical dictionaries. In 1842, Erasmus Wilson separated acne simplex (acne vulgaris) from 
acne rosacea [4].
3. Epidemiology
Between 30 and 50% of adolescents experience psychological difficulties associated with acne, 
including body image concerns, embarrassment, social impairment, anxiety, frustration, 
anger, depression, and poor self-esteem [5]. The prevalence of body dysmorphic disorder 
among acne patients has been measured to be as high as 21% in some office settings [6], and 
these patients are more likely to report dissatisfaction with dermatologic treatment, attempt 
suicide, and threaten health-care providers both legally and physically [7, 8].
Acne vulgaris affects approximately 40–50 million individuals each year in the USA, with an 
estimated cost of $2.5 billion annually. The disease affects approximately 85% of young people 
between 12 and 24 years of age and often tends to continue into the adulthood. In a survey-
based study, 35% of women and 20% of men reported having acne in their thirties, while 26% 
of women and 12% of men were still affected in their forties [9]. Males of Caucasian origin 
have a tendency to have more severe nodulocystic disease than other groups. Individuals 
with XYY karyotype or endocrine disorders such as polycystic ovarian syndrome, hyperan-
drogenism, hypercortisolism, and precocious puberty are at increased risk for acne develop-
ment, with a more resistant clinical course.
4. Pathogenesis
The development of acne involves a complex interaction of multiple factors within the pilo-
sebaceous gland. Understanding the anatomy and physiology of this unique structure is vital 
to understanding the pathogenesis of acne and important for formulating effective treatment 
regimens.
Acne vulgaris is a disease of pilosebaceous units. Major hypotheses on its pathophysiology 
include the following [10, 11]:
1. Altered follicular keratinization (hyperkeratinization) of the pilosebaceous unit [12]
2. Propionibacterium acnes (P. acnes) follicular colonization and activity [13]
3. Hormonal influence [14, 15]
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4. Sebum production [16]
5. Release of inflammatory mediators [13, 17]
4.1. Genetic factors
The pathogenesis of acne is multifactorial, and the precise role of genetic predisposition is 
uncertain. The number, size, and activity of sebaceous glands are inherited. In addition, the 
concordance rate for the prevalence and severity of acne among identical twins is very high. 
Variable studies have shown strong association between moderate to severe acne and family 
history [18]. However, because of the high prevalence of acne, it is difficult to attribute its 
presence only to genetic factors.
4.2. Sebum production
The sebaceous gland is controlled primarily by hormonal stimulation. After the first 6 months 
of life (when sebum production is relatively high), the rate decreases and remains stable 
throughout childhood. At adrenarche, sebum production dramatically increases. Although 
the overall composition of sebum is the same in persons with or without acne, those with acne 
have variable seborrhea [19].
The sebaceous glands exude lipids by disintegration of entire cells, a process known as holo-
crine secretion. The life span of a sebocyte from cell division to holocrine secretion is approxi-
mately 21–25 days [20]. Human sebum, as it leaves the sebaceous gland, contains squalene, 
cholesterol, cholesterol esters, wax esters, and triglycerides. During passage of sebum through 
the hair canal, bacterial lipases from P. acnes hydrolyze some of the triglycerides, so that the 
lipid mixture reaching the skin surface contains free fatty acids (FFA) and small proportions of 
mono- and diglycerides in addition to the original components. The precise function of sebum 
in humans is unknown. Cunliffe and Shuster proposed that sebum’s solitary role is to cause 
acne [21]. Another theory suggests that sebum reduces water loss from the skin’s surface and 
functions to keep skin soft and smooth. The sebaceous gland-deficient mouse (Asebia) model 
provides evidence that glycerol derived from triglyceride hydrolysis in sebum is critical for 
maintaining stratum corneum hydration [22], but there is no evidence for this in humans as 
stratum corneum hydration is normal during periods, such as, childhood when the gland is 
quiescent. Similarly, vitamin E delivery to the upper layers of the skin protects the skin and 
its surface lipids from oxidation; thus, sebum flow to the surface of the skin may provide the 
transit mechanism necessary for vitamin E to function [23]. Recent evidence suggests that 
sebaceous glands and sebum play a role in the skin’s innate immunity. Sebum is known to 
have mild antibacterial action, presumably due to the presence of immunoglobulin A [24]. 
Recent studies show that FFA in human sebum is bactericidal against Gram-positive organ-
isms as a result of its ability to increase antimicrobial peptide, b-defensin 2 (HBD2) expression 
[25]. Additional antimicrobial peptides including cathelicidin, psoriasin, b-defensin 1, and 
b-defensin 2 are expressed within the sebaceous gland. Functional cathelicidin peptides have 
direct antimicrobial activity against P. acnes but also initiate cytokine production and inflam-
mation in the host organism [26, 27]. Innate immune Toll-like receptors 2 and 4 (TLR2, TLR4) 
and CD1d and CD14 molecules are also expressed in sebaceous glands [28]. All these findings 
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provide evidence that the sebaceous gland may play an important role in pathogen recogni-
tion and protection of the skin surface.
The exact mechanisms underlying the regulation of human sebum production are not fully 
defined. Results from a variety of experimental models clearly indicate that sebaceous glands 
are regulated by androgens and retinoids. Recent evidence suggests that peroxisome pro-
liferator activated receptors, melanocortins, corticotropin-releasing hormone, and fibroblast 
growth factor receptors play a role as well.
The role of sebum in the pathogenesis of acne is closely associated with the activity of P. 
acnes. The microenvironment within the sebaceous gland is anaerobic and favors the survival 
of P. acnes bacteria over others (i.e., Staphylococcus epidermidis). The P. acnes bacterium relies 
on sebaceous lipids as a nutrient source and breaks down triglycerides into FFA, which can 
be irritating and contribute to the inflammatory response [29, 30]. Furthermore, it is demon-
strated that P. acnes is capable of stimulating the production of both proinflammatory cyto-
kines/chemokines and antimicrobial peptides from keratinocytes and cultured sebocytes, 
indicating that keratinocytes and sebocytes themselves may play a role in the inflammatory 
aspects of acne [31, 32].
4.3. Comedo formation
First step of acne production is the formation of microcomedo, which begins in the infun-
dibulum, the keratinized lining of the upper portion of the follicle. The corneocytes are nor-
mally shed into the lumen of the follicle and extruded through the follicular ostium. When 
they are retained and accumulated, this leads to hyperkeratosis. Lamellar granules, cell 
membranes, epidermal lipids, and intercellular cementing substances all play a role in the 
increased adhesiveness of these cells. In addition to increased intercellular cohesiveness of 
the corneocytes, their production is also accelerated. In the proximal portion of the infundib-
ulum, the infrainfundibulum, combination of increased cellular cohesion, and proliferation 
creates a bottleneck phenomenon and subsequent microcomedo formation. In the underly-
ing follicular epithelium, keratohyaline granules are increased in size and number, whereas 
lamellar granules and tonofilaments are decreased. As the comedo expands, the sebaceous 
lobule undergoes regression. Because of the very narrow opening to the skin surface, there is 
initially an accumulation of loosely packed shed keratinocytes and sebum. With expansion of 
the comedo, the contents become closely packed, creating whorled lamellar concretions. With 
increased pressure, rupture of the comedo wall leads to extrusion of the immunogenic keratin 
and sebum, with resultant inflammation.
4.4. Inflammatory responses
Inflammation is not always a result of comedo rupture and can also be observed in early 
acne lesions. Prior to hyperkeratinization, the number of CD4+ T cells and levels of inter-
leukin-1 (IL-1) have been shown to be increased perifollicularly, especially in acne-prone 
sites [33]. If neutrophils predominate (typical of early lesions) in the lesion, a suppurative 
pustule is formed. Neutrophils also promote the inflammatory response by releasing lyso-
somal enzymes and generating reactive oxygen species, which directly correspond with acne 
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 severity [34]. Influx of lymphocytes (predominately T-helper cells) and foreign body-type 
giant cells, together with neutrophils result in inflamed papules, nodules, and cysts. Genetics 
are likely to play a role as not all patients with inflammatory acne will scar and patients often 
report that their parents also have severe scarring from acne in their youths. Data suggest 
that the likelihood of scarring is associated with the type of inflammatory response. Early, 
nonspecific inflammation results in less scarring whereas delayed and specific inflammatory 
response lead to permanent scar tissue [35]. Holland et al. observed that in inflammatory 
lesions from patients who have less scarring, there is a brisk inflammatory cellular infiltrate 
composed of T-helper lymphocytes, macrophages, and Langerhans cells, with accompanying 
angiogenesis that quickly resolves compared with patients who are prone to scarring, where 
the inflammation and angiogenesis start slowly but is maintained over a longer period. It 
is speculated that the prolonged inflammatory response in patients prone to scarring is a 
delayed-type hypersensitivity reaction to persistent antigenic stimulus that they were initially 
unable to eliminate [36]. As there is no tool to predict who will develop this delayed-type reac-
tion, treating early inflammation is the best approach to prevent acne scarring.
4.5. Propionibacterium acnes and the innate immune system
These Gram-positive, non-motile rods which contributes significantly to the pathogenesis of 
acne are found deep within the sebaceous follicle, along with Propionibacterium granulosum 
and, rarely, Propionibacterium parvum. They are anaerobic/microaerophilic and naturally pro-
duce porphyrins (primarily coproporphyrin III) that fluoresce with Wood’s lamp illumina-
tion. These microorganisms release enzymes contributing to comedo rupture, lipases and 
chemotactic factors, and stimulate host response by inflammatory cells and keratinocytes 
leading to production of proinflammatory mediators and reactive oxygen species. In acne 
patients, the number of P. acnes cases is increased, but their numbers do not correlate with 
clinical severity [37]. Different strains of P. acnes have been shown to induce varying degrees 
of sebocyte differentiation and proinflammatory cytokine/chemokine responses [32].
Interactions between the skin’s innate immune system and P. acnes play an important role 
in acne pathogenesis. One mechanism is via Toll-like receptors (TLRs), a class of transmem-
brane receptors that mediates the recognition of microbial pathogens by immune cells such as 
monocytes, macrophages, and neutrophils as well as by keratinocytes. TLR2 is found on the 
surface of macrophages surrounding acne follicles, and P. acnes has been found to increase 
expression of TLR2 and TLR4 on keratinocytes. P. acnes has been shown to stimulate the 
release of proinflammatory mediators (e.g. IL-1α, IL-8, IL-12, tumor necrosis factor-α [TNF-α], 
matrix metalloproteinases) through the TLR2 pathway [38–40]. IL-8 results in neutrophil 
recruitment, the release of lysosomal enzymes and subsequent disruption of the follicular 
epithelium, whereas IL-12 promotes Th1 responses. The degree to which IL-8, IL-12, and 
interferon-γ production is augmented does not appear to depend upon the strain of P. acnes 
that is present [40, 41]. In contrast, certain strains of P. acnes may have an increased propen-
sity, to upregulate expression of human β-defensin-2 by the pilosebaceous unit via a TLR-
dependent mechanism [42]. Beta-defensin-2 cathelicidins and other antimicrobial peptides 
such as psoriasin work synergistically to protect the pilosebaceous unit from P. acnes [26, 43]. 
Histone H4, which is secreted in a holocrine manner by sebocytes, also directly kills P. acnes 
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and may function together with free fatty acids to augment innate immune defenses [44]. 
Lastly, P. acnes can induce monocytes to differentiate into two distinct innate immune cell 
subsets: (1) CD209+ macrophages (development of which is promoted by tretinoin) that more 
effectively phagocytose and kill P. acnes and (2) CD1b+ dendritic cells that activate T cells and 
release proinflammatory cytokines [45].
All these new findings about the role of innate immunity on acne formation build upon tradi-
tionally known pathogenetic factors can be summed up as follows;
1. Inflammatory events mediated by interleukin-1 precede hyperkeratinization
2. P. acnes activates the innate immune system via Toll-like receptors
3. P. acnes induces matrix metalloproteinase and antimicrobial peptide production
4. Sebaceous gland lipids influence the innate immune system.
4.6. Hormonal influences
Sebum secretion is under direct influence of hormonal factors. Androgens are pro-
duced primarily from the gonads and adrenal glands but also locally via the enzymes of 
3β-hydroxysteroid dehydrogenase (HSD), 17β-HSD and 5α-reductase. Androgen receptors, 
found in the cells of the basal layer of the sebaceous gland and the outer root sheath of the 
hair follicle, are responsive to testosterone and 5α-dihydrotestosterone (DHT). DHT is the 
principal androgen mediating sebum production and has a 5–10-fold greater affinity than 
testosterone for the androgen receptor. The role of androgens in sebaceous gland activity 
begins during the neonatal period. With the onset of adrenarche (typically at 7–8 years of age, 
usually heralding menarche by several years), circulating levels of DHEAS begin to rise due 
to adrenal production. This hormone can serve as a precursor for the synthesis of more potent 
androgens within the sebaceous gland. The rise in serum levels of DHEAS in prepubescent 
children is associated with an increase in sebum production and the initial development of 
comedonal acne [46]. The exact mechanism of how estrogens modulate sebum production 
is not known. Any estrogen given systemically in sufficient amounts will decrease sebum 
production. However, the dose of estrogen required to suppress sebum production is greater 
than the dose required to suppress ovulation. Although acne may respond to treatment with 
lower-dose oral contraceptives containing 0.035–0.050 mg of ethinyl estradiol or its esters, 
higher doses of estrogen are often required to demonstrate a reduction in sebum secretion 
[47]. Estrogens may inhibit the effects of androgens locally within the sebaceous gland or via 
a negative feedback loop whereby pituitary gonadotropin release is inhibited.
4.7. Dietary factors
It has long been posited that diet has no impact on acne, but recent clinical trials have sug-
gested that a relationship does indeed exist. The relationship between diet and acne has always 
been controversial. The association between glycemic load and acne is especially convincing. 
Prospective studies have documented a link between a high glycemic-load diet and acne risk 
[48]. Further clinical trials among a wider patient base could better define recommendations 
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for modifying carbohydrate intake, but until then, it is appropriate for dermatologists to rec-
ommend a lower glycemic load diet among patients with acne.
Although the link between dairy and acne is less convincing than high glycemic load diet, 
a recent case control study showed a positive association between low-fat/skim milk con-
sumption and acne [49]. The exact mechanism by which dairy may impact acne, whether it is 
via a hormonal pathway or upregulated IGF-1, remains to be further clarified. If physicians 
choose to counsel their patients that dairy consumption may indeed exacerbate their acne, it 
is reasonable to simultaneously advise patients to supplement their diets with vitamin D and 
calcium. The role of o-3 fatty acids, antioxidants, zinc, vitamin A, and iodine in acne vulgaris 
remains to be elucidated. Given the level of evidence available if a particular patient notes 
an association between a certain dietary factor and acne severity, it is best to support that 
patient’s dietary supplementation or restriction and to encourage the patient to keep a food 
diary to test his or her hypothesis.
5. Clinical features
Acne is mostly observed on the facial area and upper trunk, areas with increased number of 
sebaceous glands (Figure 1). Comedones constitute non-inflammatory lesions of acne.
Figure 1. Acne lesions and scars are seen on the back of the patients.
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Closed comedones are small skin-colored papules with no apparent follicular opening. These 
lesions may be subtle and best diagnosed via palpation, stretching or side-lighting of the 
skin. Open comedones, on the other hand, mostly referred as blackheads, are dome-shaped 
papules with dilated follicular openings filled shed keratin. Black coloration is due to mela-
nin deposition and lipid oxidation within the debris. Inflammatory acne also originates with 
comedo formation, followed by the development of papules, pustules, nodules, and cysts 
(Figure 2).
Erythematous papules typically range from 1 to 5 mm in diameter. Pustules tend to be 
approximately equal in size and are filled with white pus and normal flora. As the severity 
of lesions progresses, nodules form and become markedly inflamed, indurated, and tender. 
Figure 2. Marked papules, pustules, and comedones are noticed.
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The cysts of acne are deeper and filled with a combination of pus and serosanguineous fluid. 
In patients with severe nodulocystic acne (Figure 3), these lesions frequently coalesce to form 
large, complex inflamed plaques that can include sinus tracts.
Early treatment of acne is essential for the prevention of lasting cosmetic disfigurement due to 
scarring. Erythema and postinflammatory hyperpigmentation often persist after resolution of 
Figure 3. Severe nodules and cysts on the face.
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inflammatory acne lesions. Pigmentary changes usually fade away in months whereas pitted 
or hypertrophic scars are often permanent.
5.1. Acne variants
5.1.1. Postadolescent acne
This form of acne mostly affects women older than 25 years of age with signs of hyperan-
drogenism and increases in severity prior to menstruation. The lesions consist of tender, 
deep-seated papulonodules on the lower third of the face, jawline, and neck [50]. Hormonal 
therapy is often effective regardless of androgen levels.
5.1.2. Acne fulminans
It is the most severe form of acne and is characterized by nodular and suppurative acne 
lesions with systemic manifestations. It primarily affects adolescent boys who typically have 
mild to moderate acne prior to the onset of acne fulminans. Numerous microcomedones 
suddenly erupt and become markedly inflamed. Most commonly affected areas are the face, 
neck, chest, back, and arms. Lesions tend to ulcerate and can lead to significant scarring. 
Osteolytic bone lesions may accompany the cutaneous findings; the clavicle and sternum are 
most commonly affected, followed by the ankles, humerus, and iliosacral joints. Systemic 
manifestations include fever, arthralgias, myalgias, hepatosplenomegaly, and severe malaise. 
The related synovitis, acne, pustulosis, hyperostosis and osteitis can be seen and is defined as 
SAPHO syndrome. Erythema nodosum may also arise in association with acne fulminans. An 
elevated ESR, proteinuria, leukocytosis, and anemia mostly accompanies and may be related 
with the clinical course and response to therapy.
Treatment of acne fulminans usually includes initial oral corticosteroid treatment, followed 
by systemic isotretinoin, after the acute inflammation subsides. During the first few weeks of 
isotretinoin therapy, acne fulminans-like flares can be observed [51]. Oral antibiotics, TNF-α 
inhibitors, and immunosuppressive agents (e.g. azathioprine) can also be used. Acne fulmi-
nans associated with erythema nodosum responds well to dapsone therapy [52].
5.1.3. Acne conglobata and associated conditions
Acne conglobata is also a severe form of nodulocystic acne that may have a sudden onset 
but without systemic manifestations. The nodules are usually found on the chest, shoulders, 
back, buttocks, upper arms, thighs, and face (Figure 4). It is a part of the follicular occlu-
sion tetrad, along with dissecting cellulitis of the scalp, hidradenitis suppurativa, and pilo-
nidal cysts. The association of sterile pyogenic arthritis, pyoderma gangrenosum, and acne 
conglobata can occur in the context of an autosomal dominant autoinflammatory disorder 
referred to as PAPA syndrome [53]. This syndrome is caused by mutations in the gene that 
encodes proline–serine–threonine phosphatase interacting protein 1 (PSTPIP1) which leads to 
the disruption of the physiologic signaling required for maintenance of a proper inflamma-
tory response [53].
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5.1.4. Solid facial edema
An unusual and disfiguring complication of acne vulgaris is solid facial edema (Morbihan’s dis-
ease). Clinically, there is a distortion of the midline face and cheeks due to soft tissue swelling 
and accompanying erythema. Due to chronic inflammation and mast cell activation, lymphatic 
drainage is impaired resulting in fibrosis. Similar changes have been described in patients with 
rosacea and Melkersson-Rosenthal syndrome. The degree of the edema may change but solid 
facial edema does not usually resolve spontaneously. Treatment options include systemic 
isotretinoin alone or together with ketotifen or systemic corticosteroids [54, 55].
Figure 4. A closer view of draining sinuses and nodules on the lower extremity.
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5.1.5. Acne mechanica
This form occurs secondary to repeated mechanical and frictional trauma causing obstruc-
tion of the pilosebaceous outlet. Rubbing by helmets, chin straps, suspenders or collars can 
be responsible for acne mechanica. Linear and geometrically distributed comedones are 
characteristic.
5.1.6. Acne excoriée des jeunes filles
Typical comedones and inflammatory papules are systematically excoriated, leaving crusted 
and linear erosions (Figure 5). An underlying psychiatric component should be considered. 
Figure 5. Excoriated inflammatory lesions are seen.
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Individuals with an anxiety disorder, obsessive–compulsive disorder or personality disorder 
are particularly at risk.
5.1.7. Drug-induced acne
Acne or eruptive acneiform lesions can be seen as a side effect of certain drugs. Characteristically 
abrupt, mono morphous eruption of inflammatory papules and pustules are observed. High-
dose intravenous or oral corticosteroids commonly induce characteristic acneiform eruptions 
with a concentration of lesions on the chest and back. Steroid-induced acne (and rosacea) can 
also result from the inappropriate use of topical corticosteroids on the face. Inflamed papules 
and pustules develop on a background of erythema that favors the distribution of corticoste-
roid application. Lesions eventually resolve following discontinuation of the corticosteroid, 
although “steroid dependency” can lead to prolonged and severe flares postwithdrawal.
5.1.8. Occupational acne, acne cosmetica
Occupational acne results from exposure to insoluble, follicle-occluding substances. Cutting 
oils, petroleum-based products, chlorinated aromatic hydrocarbons, and coal tar derivatives 
can be responsible. Comedones together with papules, pustules, and cystic lesions distributed 
in exposed as well as typically covered areas. Acne cosmetica is mostly seen as closed comedo-
nes, due to chronic occlusion of follicles with the use of cosmetics.
5.1.9. Chloracne
It is caused several weeks after the exposure to chlorinated aromatic hydrocarbons. Most com-
monly affected areas are the malar, retroauricular, and mandibular regions of the head and 
neck, axillae, and scrotum. Small cystic papules and nodules are seen and healing with scar 
tissue formation is not uncommon. The following agents, found in electrical conductors and 
insulators, insecticides, fungicides, herbicides, and wood preservatives, have all been impli-
cated: polychlorinated naphthalenes, biphenyls, dibenzofurans, and dibenzodioxins; polybro-
minated naphthalenes and biphenyls; tetrachloroazobenzene; and tetrachloroazoxybenzene.
5.1.10. Neonatal acne (neonatal cephalic pustulosis)
Neonatal acne can be observed in more than 20% of healthy newborns. Lesions usually start 
appearing 2 weeks after birth and generally resolve within the first 3 months of life. Small, 
inflamed papulopustules without comedones on the cheeks and nasal bridge are typical for 
neonatal acne. The disease responds well to topical imidazoles, and this also supports the 
inflammatory response to Malassezia spp. as a pathogenetic mechanism. The active sebaceous 
glands and high sebum excretion rate in neonates are also thought to play a role. The substan-
tial decline in sebum production after the first few months of life helps to explain the limited 
period of susceptibility to neonatal acne.
5.1.11. Infantile acne
Infantile acne occurs after 3 months of age and usually persists until the end of first year. In 
contrast to neonatal acne, comedo formation is prominent and pitted scarring can develop.
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Deep cystic lesions and suppurative nodules are occasionally seen. Androgen production due 
to elevated levels of LH stimulating testicular production of testosterone in boys and elevated 
levels of DHEA produced by the infantile adrenal gland in both boys and girls is responsible 
from acne formation. These androgen levels normally decrease substantially by 12 months of 
age and remain at low levels until adrenarche. Thus infantile acne typically resolves within 
1–2 years and remains quiescent until around puberty. Topical retinoids (e.g., tretinoin, ada-
palene) and benzoyl peroxide are first-line treatments for infantile acne. Oral antibiotics (e.g. 
erythromycin, azithromycin) can be helpful for patients with a more severe inflammatory 
component, and isotretinoin is occasionally required for recalcitrant cases [56].
5.1.12. Endocrinologic abnormalities
Hyperandrogenism should be suspected in female patients with hirsutism or irregular 
menstrual periods, as well as in children who develop acne between 2 and 7 years of age. 
Hyperandrogenism-originated acne is often severe and resistant to therapy. Other signs and 
symptoms of hyperandrogenism in women and children include coarsening of the voice, a 
muscular habitus, androgenetic alopecia, clitoromegaly with variable posterior labial fusion, 
and increased libido. Insulin resistance and acanthosis nigricans can occur in association with 
hyperandrogenism in the HAIR-AN syndrome. These patients are at increased risk for accel-
erated cardiovascular disease and diabetes mellitus. Initial laboratory tests of serum levels 
of total and free testosterone, DHEAS, and 17-hydroxyprogesterone can give an idea about 
the source of excess androgens. An elevated serum DHEAS or 17-hydroxyprogesterone level 
indicates an adrenal problem such as congenital adrenal hyperplasia or an adrenal tumor. If 
the testosterone levels (total and free) are elevated and the DHEAS level is relatively normal, 
an ovarian source is likely. Polycystic ovary syndrome (PCOS) is the most common condition 
associated with an elevated serum testosterone level.
6. Pathology
Histopathologic stages of acne lesions show a parallel course with the clinical findings. In 
early lesions, microcomedones are seen. A mildly distended follicle with a narrowed follicu-
lar opening is impacted by shed keratinocytes. In closed comedones, the degree of follicular 
distension is increased and a compact cystic structure with eosinophilic keratinaceous debris, 
hair, and numerous bacteria is formed. Open comedones have broad, expanded follicular 
ostia and overall an increased follicular distension. Perivascular mononuclear cell infiltrate 
circles the expanding follicle. As the follicular epithelium distends, highly immunogenic cys-
tic contents rupture into the dermis, inducing a marked inflammatory response. Neutrophils 
first appear, creating a pustule. As the lesion matures, scarring due to foreign body granulo-
matous inflammation can be seen.
7. Differential diagnosis
Differential diagnosis of acneiform eruptions is broad and depends upon the age of onset, 
lesional morphology, and location. During the neonatal period, acne must be  differentiated 
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from other similar dermatoses including sebaceous hyperplasia and miliaria rubra. 
Predominantly comedonal acne vulgaris needs to be differentiated from comedonal erup-
tions caused by follicular occlusion or friction, including pomade and occupational acne, 
acne cosmetica and acne mechanica. Multiple open comedones are clustered in the lateral 
malar region in Favre-Racouchot disease or appear in a linear array in nevus comedonicus. 
Angiofibromas and appendageal tumors of follicular origin like trichoepitheliomas, trichodis-
comas, and fibrofolliculomas, often present as multiple noninflammatory facial papules. 
Steatocystoma multiplex is also characterized by noninflammatory, closed cystic papules and 
nodules on the central chest and back. The follicle-based inflammatory papules and pustules 
of acne vulgaris must be distinguished from the many forms of folliculitis, including staphy-
lococcal, Gram-negative, and eosinophilic variants. Folliculitis lesions are typically mono-
morphous and comedones are not present. Acne vulgaris treated with oral antibiotics for a 
prolonged period can complicate with Gram-negative folliculitis. The papular component of 
rosacea favors the malar region, chin, and forehead; the presence of telangiectasias, absence 
of comedones and a history of easy flushing can lead to diagnosis. Prolonged use of topical 
corticosteroids on the face may lead to rosacea-like lesions or perioral/periorificial dermatitis, 
and patients treated with oral corticosteroids can develop an eruption of monomorphous 
papulopustules that favors the trunk.
8. Treatment
Acne can have devastating physical as well as emotional effects and the treatment course of 
acne vulgaris requires a high degree of compliance. Thus it is critical that the patient be made 
aware of the nature of the disease process and what is to be expected from the treatment 
regimen prescribed. A complete history and physical examination are key to developing an 
appropriate and effective treatment plan. A review of all prescription and over-the counter 
medications used for acne or other conditions, and clinical responsiveness to them, together 
with cosmetics, sunscreens, cleansers, and moisturizers is also helpful. In female patients, a 
menstrual and oral contraceptive history is important in determining hormonal influences on 
acne. On physical examination, careful note should be taken of lesion morphology, includ-
ing the presence of comedones, inflammatory lesions, nodules, and cysts. Secondary changes 
such as scarring and postinflammatory pigmentary changes are also important clinical find-
ings. The patient’s skin color and type can also influence the chosen formulation of a topical 
medication.
8.1. Topical treatments
8.1.1. Topical retinoids
Topical retinoids used for the treatment of acne vulgaris will be discussed in elsewhere.
8.1.2. Benzoyl peroxide and other topical antibacterial agents
Benzoyl peroxide (BPO) is still the gold standard for mild-to-moderate acne. It is the leading 
over the counter anti-acne agent in the United States. Different preparations including bar 
soaps, washes, gels, lotions, creams, foams, and pads with concentrations ranging from 2.5 
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to 10% are available as well as products which combine benzoyl peroxide with clindamycin, 
erythromycin, or adapalene. BPO is a bleaching agent, thus whitening of clothing and bed-
ding can occur. İrritant or allergic contact dermatitis can develop to benzoyl peroxide, pre-
senting with marked erythema. BPO is a potent bactericidal agent that reduces P. acnes within 
the follicle. It also has mild comedolytic properties and is particularly effective when used in 
combination with other therapies.
The mechanism of action is presumably due to its strong oxidizing property. The release of 
free oxygen radical causes oxidation of bacterial proteins and the development of oxygen cre-
ates a milieu in the follicle, where anaerobic bacteria like P. acnes cannot survive [57–60]. BPO 
has a broad-spectrum and rapid activity against Gram-positive and Gram-negative bacteria, 
yeasts, and various fungi [58]. Significant and fast reduction in the number of propionibacte-
ria from the skin surface and follicular casts can be achieved with topical use of BPO, starting 
within days after the initiation of the therapy. However, long-term use of the agent does not 
provide further decrease in the bacterial population [61–63].
Unlike common antibiotics, BPO is effective and can be readily used against antibiotic-resis-
tant propionibacteria strains [60]. This agent shows its antibacterial action via powerful oxi-
dation. This nonspecific mode of antibacterial action does not lead to the development of 
resistant strains and thus makes long-term use of the drug possible [62]. Therefore, in order 
to sustain long-lasting efficacy in acne therapy, broad-spectrum antibacterial agents such as 
BPO can be used concomitantly or sequentially with antibiotics. Unlike bacterial burden, BPO 
has a lack of direct effect on sebum production and does not reduce skin surface lipids, but 
it is effective in reducing the free fatty acids, known as comedogenic agents, and triggers of 
inflammation in sebum [64, 65]. BPO is thought to have weak comedolytic activity [66].
Another supplementary benefit of BPO in acne therapy is its anti-inflammatory action. BPO, 
however, does not have significant direct in vivo anti-inflammatory potency. A potential expla-
nation for the anti-inflammatory effects of BPO could be the mediation by the antibacterial or 
oxidizing action of BPO. Following the decrease in the population of P. acnes in the follicles 
and the reduction of free oxygen radicals, one source of inflammation is cut and therefore 
inflammatory reactions are suppressed. The anti-inflammatory benefit of BPO, regardless of 
being direct or indirect, is reflected in several studies [67].
BPO products are indicated for mild-to-moderate acne with occurrence of predominantly 
inflamed lesions. One study tested different BPO formulations with different concentrations 
and at the end of 4 weeks treatment, they were all shown to decrease the number of papules 
and pustules and, to a smaller degree, the number of comedones [68]. Not only efficacy in 
mild-to-moderate acne but also a rapid onset of action can be observed after BPO application, 
which accompanies the quick antibacterial action within the first week of therapy [69].
8.1.3. Topical antibiotics
Topical antibiotics have been an integral component of the topical acne treatment. Over 
time, the most common topical antibiotics used for acne treatment have been erythromy-
cin and clindamycin, with the latter being favored over the past several years, primarily 
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due to  widespread emergence globally of P. acnes strains resistant to erythromycin [70]. 
Sulfacetamide with or without sulfur has also been used topically for treatment of acne vul-
garis but data regarding the efficacy of these agents are limited. It is thought to restrict the 
growth of P. acnes through competitive inhibition of the condensation of para-aminobenzoic 
acid with pteridine precursors.
The principal mechanism of action of topical antibiotics appears to be through reduction 
in P. acnes organisms, which reduces the subsequent triggering of inflammatory activities 
[71, 72]. The use of benzoyl peroxide in combination with erythromycin or clindamycin aug-
ments reduction in P. acnes, reduces the emergence of resistant P. acnes strains, and may 
improve efficacy over use of either agent alone [71].
Concerns regarding emergence of clinically significant antibiotic-resistant bacteria primarily 
focus on systemic antibiotic use but topical antibiotic use can also change the cutaneous flora as 
application of topical antibiotics for treatment of acne is usually continued over several months 
to years [73, 74]. Thus, progressive emergence of normal bacterial flora that are less antibiotic 
sensitive such as macrolide-resistant Staphylococcus epidermidis and erythromycin- and tetracy-
cline-resistant P. acnes strains has an estimated prevalence of 40% globally over approximately 
three decades [74]. Additionally, antibiotic-resistant P. acnes strains have been demonstrated on 
skin of untreated contacts of acne patients treated with topical antibiotic therapy, supporting 
interpersonal spread [75]. The clinically relevant effects of these changes in normal bacterial 
flora secondary to antibiotic use are not entirely clear. However, there is evidence for a cor-
relation between antibiotic-resistant P. acnes and a reduction in efficacy with antibiotic therapy 
[73, 74]. Potential issues of concern that have been raised in this manner include increased prev-
alence of P. acnes strains less responsive to antibiotics, alterations in cutaneous flora, decreased 
therapeutic responsiveness to antibiotic therapy, and promotion of other clinical infections 
among treated patients and/or their close contacts. Apart from these, pharyngeal colonization 
with Streptococcus pyogenes and a possible increased risk of an upper respiratory tract infection 
have been associated with chronic use of antibiotics for acne, including topical agents [76, 77].
A report analyzing several monotherapy studies using either topical erythromycin or topical 
clindamycin for acne vulgaris demonstrated that the efficacy of topical erythromycin in reduc-
ing acne lesions has markedly decreased over time; however, the efficacy of topical clindamy-
cin has not diminished on the basis of the same parameters of acne lesion reduction [78].
Topical antibiotics remain an important part of acne treatment and are recommended as a 
component of combination topical therapy; monotherapy with a topical antibiotic for acne is 
not recommended. At present, topical clindamycin remains the predominant topical antibi-
otic used for acne treatment; however, other agents such as erythromycin, sulfacetamide with 
or without sulfur, and azelaic acid are also options. Overall, the tolerability and safety profiles 
of topical antibiotics used for the treatment of acne vulgaris, are very favorable.
8.1.4. Azelaic acid
Azelaic acid is a naturally occurring dicarboxylic acid found in cereal grains. It is available as 
a topical 20% cream formulation, which has been shown to be effective in inflammatory and 
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comedonal acne [10]. By inhibiting the growth of P. acnes, azelaic acid reduces inflammatory 
acne. It also reverses the altered keratinization of follicles affected by acne and thus demon-
strates comedolytic properties. The activity of azelaic acid against inflammatory lesions may 
be greater than its activity against comedones. Overall, the position of azelaic acid in the 
treatment algorithm of acne vulgaris has been as an alternative to other topical agents. Initial 
improvement in acne with topical azelaic acid has been reported to be observed in 4–8 weeks, 
with maximum benefit generally noted after approximately 16 weeks of use [79]. Azelaic acid 
is applied twice daily, and its use is reported to have fewer local side effects than topical reti-
noids. In addition, it may help to lighten postinflammatory hyperpigmentation.
8.1.5. Salicylic acid
Salicylic acid (SA) is a comedolytic and mild anti-inflammatory agent, widely used as a topical 
therapeutic agent for a variety of skin diseases, including acne, psoriasis, dandruff, and ich-
thyosis. Concentrations ranging from 0.5 to 10% have been recommended for acne, in numer-
ous delivery formulations, including gels, creams, lotions, foams, solutions, and washes. The 
action of SA may occur due to the reduced cohesion between corneocytes, resulting in the 
shedding of epidermal cells, rather than “lysing” of keratin [80]. The antibacterial action of SA 
against P. acnes has also been demonstrated in both in vitro and in vivo studies. Side effects of 
topical salicylic acid include erythema and scaling.
Many clinical studies have proven the anti-acne efficacy of SA-containing products. SA can 
induce a more rapid effect on noninflamed lesions, when compared to inflamed lesions, which 
strengthens the suggestion that it has a primary effect on comedogenesis [81]. According to 
cross-over studies, SA is slightly more effective than BPO for the treatment of comedonal 
acne, as well as inflammatory lesions [82, 83]. The observed superiority of SA might be due 
to its mode of action. Since the primary lesion of acne is the microcomedo, a treatment that is 
effective in preventing its formation will be effective in preventing inflammatory lesions into 
which the microcomedo can progress. As the action of SA is mainly keratolytic, it interferes in 
an earlier stage than BPO, and in consequence it seems to be superior in acting against later 
steps, the inflamed lesions.
8.1.6. Topical dapsone
Topical dapsone 5% gel is approved for the treatment of acne vulgaris. Of note, a temporary 
yellow-orange staining of the skin and hair occasionally occurs with concomitant use of topi-
cal dapsone and benzoyl peroxide.
8.2. Oral treatments
8.2.1. Antibiotics
Current basic clinical research including identification of the P. acnes genome, analysis of 
innate-immune response in acne inflammation, evaluation of the role of inflammation in 
comedogenesis, and microbiologic studies correlating P. acnes with specific treatments and 
therapeutic benefit, all support the goal of P. acnes suppression with antimicrobial therapy as 
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a component of acne management [72]. In addition to P. acnes suppression, some antibiotics 
such as the tetracycline derivatives also exhibit anti-inflammatory properties that appear to 
contribute to their therapeutic benefit in acne vulgaris [84].
Conventionally, the predominant oral antibiotics used for treatment of acne vulgaris in most 
countries have been tetracycline, doxycycline, minocycline, erythromycin, azithromycin, and 
rarely trimethoprim. Doxycycline and minocycline are used more frequently than tetracycline 
and erythromycin due to resistance issues but over time there has been a trend toward an 
increase in P. acnes strains becoming less sensitive to doxycycline and minocycline as well 
[74, 85, 86] (Table 1).The greatest decrease in P. acnes colony counts has been demonstrated 
with minocycline, followed in order of magnitude by doxycycline, tetracycline, trimethoprim-
sulfamethoxazole, and erythromycin [87]. The clinical efficacy of oral antibiotic therapy for 
acne vulgaris is well established and recognized as a conventional component of rational acne 
treatment.
The main indication for oral antibiotic therapy in acne vulgaris is moderate-to-severe inflam-
matory involvement on the face and/or trunk [72]. Antibiotic monotherapy should be avoided 
due to promotion of antibiotic-resistant bacterial strains, with oral antibiotic therapy best 
utilized in combination with a topical regimen, namely benzoyl peroxide or a topical reti-
noid [88]. It has also been suggested that a short course of benzoyl peroxide therapy prior to 
initiating antibiotic therapy assists in the eradication of antibiotic-resistant P. acnes strains, 
thus enhancing the overall efficacy of antibiotic treatment. The combination therapy may also 
allow for better ability to discontinue the oral antibiotic at some point based on response to 
treatment, and hopefully allow the topical regimen alone to maintain control of acne.
If not enterically coated, doxycline, especially the hyclate salt, is best administered with food 
and a large glass of water when the patient is upright and not prior to anticipated reclining 
for at least a few hours, to reduce the risk of gastrointestinal side effects such as esophagi-
tis. Concomitant administration of doxycycline and minocycline with iron supplements and 
metal ions may decrease absorption of both agents. Azithromycin, on the other hand, does 
not as commonly cause gastrointestinal side effects, and is best taken on an empty stomach to 
maximize absorption.
In case of resistance challenges, it is important to recognize that a direct correlation between 
prevalence of P. acnes resistance and poor therapeutic response to antibiotic therapy has not 
always been consistent [74]. Factors potentially associated with a reduced response to antibi-
otic therapy may include pre-existing antibiotic resistance, the quantity of antibiotic-resistant 
Drug Usual dosage range
Minocycline (immediate release) 50–100 mg once or twice daily
Minocycline (extended release) 1 mg/kg/day (45–135 mg once daily)
Doxycycline 75–100 mg once or twice daily
150 mg once daily
Table 1. The recommended dosing schedule is seen.
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P. acnes strains in the individual patient, resistance to multiple antibiotics, use of antibiotics 
without concomitant use of benzoyl peroxide, repeated courses of antibiotic therapy especially 
without concomitant use of benzoyl peroxide, unnecessary switching of oral antibiotic agents 
despite previous efficacy, individual drug characteristics such as GI absorption and lipophilic-
ity, relative effects on serum and tissue levels due to interference of GI absorption by co-admin-
istered chelating metal ions, and existence of P. acnes in a protective extracellular biofilm in vivo.
When oral antibiotic therapy is incorporated with a topical regimen for acne, it has been sug-
gested that it be administered over a minimum period of 6–8 weeks and a maximum of 12 
weeks–6 months. In the initial follow-up 6–8 weeks after the start of therapy, if a substantial 
lack of efficacy is observed despite adequate compliance, a change in oral antibiotic therapy 
is reasonable [72, 74, 89]. If partial improvement is observed, it may be reasonable to con-
tinue with the current therapy for an additional 6–8 weeks to evaluate if further progress is 
achieved. Changing a regimen too frequently often results in suboptimal outcomes as a given 
regimen is never afforded a true opportunity to initiate its therapeutic effect. Once control 
of acne is felt to be stable, which is usually achieved over a duration of 3–6 months assum-
ing compliance is adequate, discontinuation of the oral antibiotic therapy may be suggested, 
with continuation of the topical regimen for long-term maintenance. Stabilized control of acne 
does not necessarily imply complete clearance but may be defined as the observation that 
new inflammatory lesions have stopped or markedly decreased. Despite the alleged use of a 
topical maintenance regimen, some patients return with an acne flare within a few weeks to 
months after discontinuation of the oral antibiotic. In such cases, it is suggested to reinitiate 
therapy with the same oral antibiotic that was previously effective.
Use of systemic antibiotics may cause some adverse reactions. Doxycycline is associated with 
dose-related phototoxicity, whereas minocycline causes acute vestibular adverse events, 
lupus-like syndrome, together with cutaneous and/or mucosal hyperpigmentation, includ-
ing brown, gray, or blue pigmentation of skin and/or mucosa and blue discoloration of acne 
scars. There are no specific recommendations to routinely perform baseline or periodic labo-
ratory testing with oral antibiotics used to treat acne vulgaris; however, medical history of 
the individual patient may prompt the clinician to avoid use of a specific oral antibiotic or to 
incorporate baseline and/or periodic laboratory monitoring.
Overall, the efficacy and safety of conventional oral antibiotic therapy used for acne have been 
very favorable based on available studies and extensive clinical experience over many years.
8.2.2. Hormonal therapy
Hormonal therapy is an established second-line treatment for female patients with acne and 
can be very effective, irrespective of whether or not the serum androgen levels are abnor-
mal. Hormonal therapies are most effective in adult women with inflammatory papules and 
nodules of the lower face and neck that tend to flare prior to menstruation. These lesions are 
usually resistant to oral antibiotherapies, thus hormonal therapy with oral contraceptives to 
block both ovarian and adrenal production of androgens can be initiated. Due to potential 
long-term risks associated with oral contraceptive use consultation with a gynecologist is 
recommended. Most oral contraceptive formulations combine an estrogen with a progestin in 
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order to minimize the risk of endometrial cancer, which is known to occur with unopposed 
estrogen administration. Second-generation progestins with low intrinsic androgenic activity 
such as ethynodiol diacetate, norethindrone, and levonorgestrel are preferred in the combina-
tions. Newer, third-generation progestins like desogestrel, norgestimate, and gestodene have 
even less androgenic activity and other progestins like drospirenone, cyproterone acetate, 
and dienogest have antiandrogenic properties.
Three oral contraceptives are currently FDA-approved for the treatment of acne, although 
others also have evidence of efficacy. The first is a triphasic oral contraceptive composed of a 
norgestimate-ethinyl estradiol (35 mcg) combination. The second contains a graduated dose 
of ethinyl estradiol (20–35 mcg) in combination with norethindrone acetate, while the third 
contains a stable dose of ethinyl estradiol (20 mcg) plus drospirenone (3 mg) with a 24-day 
dosing regimen [90]. Side effects of oral contraceptives include nausea, vomiting, abnormal 
menses, weight gain, and breast tenderness; agents containing drospirenone can lead to ele-
vations in serum potassium levels, but this is generally not clinically significant in otherwise 
healthy individuals. Rare but more serious complications include hypertension and throm-
boembolism [91–93]. The progestational antiandrogen cyproterone acetate primarily makes 
androgen receptor blockade. The standard formulation combines cyproterone acetate (2 mg) 
with ethinyl estradiol (35 or 50 mcg) in an oral contraceptive formulation, which is the treat-
ment of choice for sexually active women with hormonally responsive acne [94].
Spironolactone functions as both an androgen receptor blocker and an inhibitor of 
5α-reductase. In doses of 50–100 mg twice daily, it has been shown to reduce sebum produc-
tion and improve acne [95]. Side effects are dose-related and include potential hyperkalemia, 
irregular menstrual periods, breast tenderness, headache, and fatigue. However, hyperkale-
mia is rare in young healthy patients. Because it is an antiandrogen, there is a risk of feminiza-
tion of a male fetus if a pregnant woman takes this medication. The potential risk to a fetus 
and the symptoms of irregular menstrual bleeding can be alleviated by combining spirono-
lactone with an oral contraceptive. Side effects can also be minimized if therapy is initiated 
with a low dose (25–50 mg/day). Effective maintenance doses range from 25 to 200 mg/day. 
As with other hormonal therapies, a clinical response may take up to 3 months.
Flutamide, a nonsteroidal androgen receptor blocker that is approved by the FDA for the 
treatment of prostate cancer, can also be an effective treatment for acne in women at doses 
of 62.5–500 mg/day. In addition to side effects similar to those of other antiandrogens severe 
dose-related hepatotoxicity occasionally occurs.
8.2.3. Isotretinoin
Currently, isotretinoin (13-cis-retinoic acid) is the drug of choice for the management of 
severe, treatment-resistant acne vulgaris. Treatment with isotretinoin can lead to both marked 
improvement and long-lasting remission. It was not until 1979 when Peck et al. conducted an 
open-label trial for treatment-resistant cystic and conglobate acne with isotretinoin [96] and 
shortly thereafter the Food and Drug Administration (FDA) approved isotretinoin for the 
treatment of severe nodulocystic acne. Isotretinoin, though a vitamin A derivative, is a rela-
tively water-soluble molecule. Peak plasma levels are achieved between 1 and 4 hours [97]. 
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Importantly, the magnitude of this peak level is increased by co-administration with lipids. 
Thus, patients are instructed to take their doses with a small, fatty meal. Given the half-life of 
10–20 hours, it is best to take isotretinoin twice a day [97, 98]. Isotretinoin is metabolized in the 
liver, where it is oxidized to 4-oxo-isotretinoin via CYP450 3A4 substrate and then excreted 
in urine and feces.
The primary mechanism of isotretinoin is its effect on sebaceous glands, inhibiting seba-
ceous gland activity, proliferation, differentiation, function, and production of sebum. In 
vitro studies conclude that isotretinoin induces apoptosis and cell cycle arrest of human 
sebocytes [99]. This effect seems to persist indefinitely upon completion of a full course 
(120–150 mg/kg) of isotretinoin, and this is thought to be the mode by which treatment 
with isotretinoin can cure acne. Unlike other retinoids used in dermatology, isotretinoin 
does not bind retinoic acid receptors (RARs), but functions via an RAR/RXR-independent 
mechanism. Secondary mechanisms that contribute to the efficacy of isotretinoin include 
anti-inflammatory, antibacterial (secondary to sebum reduction/alteration), and antikera-
tinizing effects.
Isotretinoin is indicated for the treatment of severe recalcitrant nodular acne, and its use for 
less severe acne is often indicated provided such cases are treatment-resistant and especially 
if the disease is leading to scarring, whether physical or emotional. In only the severest cases 
should it be considered as initial therapy.
Isotretinoin should be dosed at 0.5–1 mg/kg/day divided BID. Commonly, an initial dose 
of 0.5 mg/kg/day for the first month is preferred to acclimate the patient to mucocutane-
ous xerosis, minimize initial inflammatory response, and monitor for any adverse effects. 
The dose should then be increased to approximately 1 mg/kg/day. In patients with severe 
acne in which explosive flares may occur, pre-treatment for one or two weeks with daily 
prednisone is advised. After this pretreatment, 0.5 mg/kg/day of isotretinoin is initiated-
vwhile gradually decreasing the steroid dose. What is more important than the daily dose, 
is achieving a total cumulative dose of 120–150 mg/kg, ensuring the prolonged remission 
of acne [100].
Relapses can be observed after the completion of the therapy, especially in cases of younger 
patients, males, and truncal acne. However, acne that recurs after isotretinoin therapy is 
more responsive to less aggressive acne treatments such as topical agents or oral antibiotics. 
If still severe, a repeat course of isotretinoin can be tried with success rates similar to that 
of initial treatments. Purported relapse rates following treatment of acne with isotretinoin 
varies between 5.6 and 65.5% [101]. The most likely reasons for this large discrepancy are 
small sample size, short follow-up, retrospective design, and/or subtherapeutic cumulative 
dosage.
Absolute contraindications for isotretinoin use include pregnancy, breast-feeding, and hyper-
sensitivity to parabens, soybean oil, or other retinoids. Relative contraindications include psy-
chiatric disorders, skeletal disorders, seizure disorder, hyperlipidemia, pancreatitis history, 
diabetes mellitus, hyperuricemia, gout, and anorexia nervosa.
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Concomitant use of isotretinoin and tetracycline can induce intracranial hypertension, lead-
ing to pseudotumor cerebri, via idiosyncratic reaction. Severe and persistent headaches with 
nausea, vomiting, and blurred vision can be signs of pseudotumor cerebri.
Treatment with isotretinoin can have various adverse effects since RARs are ubiquitous 
throughout the body. These side effects mimic the effects of hypervitaminosis A and almost 
all are reversible upon discontinuation of isotretinoin. The first, and essentially universal, 
side effect of isotretinoin is cheilitis and its absence is often considered a marker of non-
compliance or insufficient dosage. Any mucocutaneous site can be affected including the 
skin, conjunctiva, oropharynx, nasopharynx, and genitalia. Treatment for mucocutaneous 
dryness consists of artificial tears for the eyes, emollients for the lips and body. Other rarely 
reported dermatological side effects of isotretinoin include photosensitivity, exuberant gran-
ulation tissue, abnormal wound healing, telogen effluvium, nail plate fragility, paronychia, 
and onycholysis.
Transient dyslipidemia is the second most common side effect after mucocutaneous xerosis. 
About 20% of acne patients treated with isotretinoin experience hypertriglyceridemia [102]. 
LDL may also be increased, while HDL may be decreased. These alterations typically occur 
early in treatment during the first month or two, stabilize, and then revert to pretreatment lev-
els upon discontinuation of isotretinoin. Substantially increased triglyceride levels can have 
risks including pancreatitis and eruptive xanthomas. Since triglyceride elevations are dose 
related, one can decrease the dose of isotretinoin. If dose reduction is not sufficient, apart 
from lifestyle changes pharmacologic therapy is indicated. The drug of choice for isotreti-
noin-induced hypertryglyceridemia is gemfibrozil, 600 mg twice daily. For triglyceride levels 
greater than 800 mg/dL, discontinuation of isotretinoin is appropriate.
Increased transaminase levels are seen in some 11–15% of acne patients treated with isotreti-
noin, whereas development of severe hepatotoxicity is extremely rare [103].
Other occasionally reported adverse effects of isotretinoin include nausea, diarrhea, abdomi-
nal pain, gastritis, proctocolitis, flares of inflammatory bowel disease, decreased white blood 
cell count, hemoglobin, and platelets, arthralgias, or myalgias.
The most serious side effect of isotretinoin is teratogenicity. It affects organogenesis; there-
fore, its greatest risk to a fetus is early in pregnancy, during the first trimester. Even one dose 
is thought to be able to induce congenital defects or spontaneous abortion [104]. The rate of 
birth defects ranges from 18 to 28%, including craniofacial, cardiac, central nervous system, 
thymic, and various other abnormalities [104–106]. Female patients of childbearing potential 
must have at least one or two negative pregnancy tests before starting treatment and practice 
effective contraception for 1 month prior to, during, and for 1 month after completing therapy.
Long-term treatment with isotretinoin can decrease bone mineral density and cause hyper-
ostosis and osteophytes. However, it is not clear if these effects apply to the short-term treat-
ment of acne with a standard course of isotretinoin [107].
In case of psychological side effects, there is no evidence that there is a causal relationship 
between mood disturbances such as depression, anxiety, or suicidal ideation and the use of 
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isotretinoin. However, there are many studies demonstrating positive and negative correla-
tion between isotretinoin use and increased risk of depression [108–112]. Nevertheless, given 
the serious nature of depression and suicidal ideation, close psychological monitoring of 
patients is recommended.
Before the initiation of isotretinoin therapy, fasting lipids and liver function tests should be 
checked at baseline, monthly for the first 2 months. If no abnormalities are found and the dose 
unchanged blood tests are done every 2 months.
8.3. Surgical treatment
Extraction of especially deep and persistent comedos can improve the cosmetic appearance 
of acne and aid in therapeutic responsiveness to topical comedolytic agents [113]. The kerati-
nous contents of open comedones may be expressed via a comedo extractor. The Schamberg, 
Unna, and Saalfield types of comedo expressers are most commonly used. Nicking the surface 
of a closed comedo with an 18-gauge needle or a #11 blade allows easier expression. This pro-
cedure should be used in conjunction with a topical retinoid or other comedolytic treatment 
for maximum benefit. Comedo extraction should not be performed on inflamed comedones 
or pustules because of the risk of scarring. Light electrocautery, electrofulguration, and cryo-
therapy can also be effective treatments for comedones.
Photodynamic therapy utilizing topical 5-aminolevulinic acid together with various light 
sources (e.g., blue, red, intense pulsed) or lasers (e.g., pulsed dye, 635 nm red diode) have 
been successfully used to treat acne [114]. In addition, blue or intense pulsed light alone and 
lasers such as the pulsed dye, the 1320 nm neodymium:YAG and especially the 1450 nm diode 
may be of therapeutic benefit for inflammatory acne.
Intralesional injection of corticosteroid (triamcinolone acetonide 2–5 mg/ml) can quickly 
improve the appearance and tenderness of deep, inflamed nodules and cysts [115]. Larger 
cysts may require incision and drainage prior to injection. The maximal amount of corticoste-
roid used per lesion should not exceed 0.1 ml. The risks of corticosteroid injections include 
hypopigmentation (particularly in darkly pigmented skin), atrophy, telangiectasias, and nee-
dle tract scarring.
Low-concentration chemical peels are also beneficial for the reduction of comedones. The 
α-hydroxy acids (including glycolic acid), salicylic acid, and trichloroacetic acid are the most 
common peeling agents. Higher-concentration glycolic acid peels (20–70%, depending on the 
patient’s skin type) and the less predictable phenol peel may also be performed in the office 
setting. Risks of chemical peels include irritation, pigmentary alteration, and scarring [116].
One of the most distressing consequences of acne vulgaris is scarring. Laser resurfacing (frac-
tional as well as traditional), dermabrasion, and deeper chemical peels can be used in case of 
scarring [117]. Surgical subscision combined with filler substances is also a commonly used 
technique in the management of “ice-pick” acne scars. For larger hypertrophic scars, aggre-
gated pitted scars, and sinus tracts, full-thickness surgical excision may result in improved 
scar placement and a better cosmetic appearance.
Acne and Acneiform Eruptions30
Author details
Zekayi Kutlubay1*, Aysegul Sevim Kecici2, Burhan Engin1, Server Serdaroglu1 and Yalcin 
Tuzun1
*Address all correspondence to: zekayikutlubay@hotmail.com
1 Istanbul University Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul, 
Turkey
2 Haydarpasa Numune Training and Research Hospital, Department of Dermatology, 
Istanbul, Turkey
References
[1] Halvorsen JA, Stern RS, Dalgard F, et al. Suicidal ideation, mental health problems, and 
social impairment are increased in adolescents with acne: a populationbased study. J 
Invest Dermatol. 2011;131:363–370. DOI: 10.1038/jid.2010.264
[2] Blau S, Kanof NB. Acne: from pimple to pit. N Y J Med. 1965;65:417–424.
[3] Goolamali SK, Andison AC. The origin and use of the word ‘acne’. Br J Dermatol. 
1977;96:291–294. DOI: 10.1111/j.1365-2133.1977.tb06140
[4] Waisman M. Concepts of acne of the British School of Dermatology prior to 1860. Int J 
Dermatol. 1983;22:126–129.
[5] Baldwin HE. The interaction between acne vulgaris and the psyche. Cutis. 2002;70:133–139.
[6] Bowe WP, Leyden JJ, Crerand CE, et al. Body dysmorphic disorder symptoms among 
patients with acne vulgaris. J Am Acad Dermatol. 2007;57:222–230. DOI: 10.1016/j.
jaad.2007.03.030
[7] Mackley CL. Body dysmorphic disorder. Dermatol Surg. 2005;33:553–558. DOI: 
10.1111/j.1524-4725.2005.31160
[8] Veale D, Boocock A, Gournay K, et al. Body dysmorphic disorder. A survey of fifty cases. 
Br J Psychiatry. 1996;169:196–201. DOI: 10.1192/bjp.169.2.196
[9] Collier CN, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20 years and 
older. J Am Acad Dermatol. 2008;58:5659. DOI: 10.1016/j.jaad.2007.06.045
[10] Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: 
an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad 
Dermatol. 2009;60:1–50. DOI: 10.1016/j.jaad.2009.01.019
[11] Oberemok SS, Shalita AR. Acne vulgaris, I: pathogenesis and diagnosis. Cutis. 
2002;70:101–105.
Acne Vulgaris
http://dx.doi.org/10.5772/65639
31
[12] Plewig G, Fulton JE, Kligman AM. Cellular dynamics of comedo formation in acne vul-
garis. Arch Dermatol Forsch. 1971;242:12–29.
[13] Vowels BR, Yang S, Leyden JJ. Induction of proinflammatory cytokines by a soluble fac-
tor of Propionibacterium acnes: implications for chronic inflammatory acne. Infect Immun. 
1995;63:3158–3165.
[14] Thiboutot D. Hormones and acne: pathophysiology, clinical evaluation, and therapies. 
Semin Cutan Med Surg. 2001;20:144–153.
[15] Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004;22:419–428. 
DOI: 10.1016/j.clindermatol.2004.03.010
[16] Thiboutot D. Regulation of human sebaceous glands. J Invest Dermatol. 2004;123:1–12. 
DOI: 10.1111/j.1523-1747.2004.t01-2
[17] Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol. 1996;106:176–182.
[18] Ghodsi SZ, Orawa H, Zouboulis CC. Prevalence, severity, and severity risk factors of 
acne in high school pupils: a community-based study. J Invest Dermatol. 2009;129:2136–
2141. DOI: 10.1038/jid.2009.47
[19] Powell EW, Beveridge GW. Sebum excretion and sebum composition in adolescent men 
with and without acne vulgaris. Br J Dermatol. 1970;82:243–249. DOI: 10.1111/j.1365-
2133.1970.tb12431
[20] Plewig G, Christophers E. Renewal rate of human sebaceous glands. Acta Dermatovener. 
1974;54:177–182.
[21] Cunliffe WJ, Shuster S. Pathogenesis of acne. Lancet. 1969;1:685–687.
[22] Flurh JW, Mao Qiang M, Brown BE, et al. Glycerol regulates stratum corneum hydration 
in sebaceous gland deficient (Asebia) mice. J Invest Dermatol. 2003;120:728–737. DOI: 
10.1046/j.1523-1747.2003.12134
[23] Thiele JJ, Weber SU, Packer L. Sebaceous gland secretion is a major physiologic 
route of vitamin E delivery to skin. J Invest Dermatol. 1999;113:1006–1010. DOI: 
10.1046/j.1523-1747.1999.00794
[24] Gebhart W, Metze D, Jurecka W. Identification of secretory immunoglobulin A in human 
sweat and sweat glands. J Invest Dermatol. 1989;92:648.
[25] Nakatsuji T, Kao MC, Zhang L, et al. Sebum free fatty acids enhance the innate immune 
defense of human sebocytes by upregulating beta defensin 2 expression. J Invest 
Dermatol. 2009;130:985–994. DOI: 10.1038/jid.2009.384
[26] Lee DY, Yamasaki K, Rudsil J, et al. Sebocytes express functional cathelicidin antimicro-
bial peptides and can act to kill Propionibacterium acnes. J Invest Dermatol. 2008;128:1863–
1866. DOI: 10.1038/sj.jid.5701235
[27] Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in 
immune defense. Trends Immunol. 2009;30:131–141. DOI: 10.1016/j.it.2008.12.003
Acne and Acneiform Eruptions32
[28] Oeff MK, Seltmann H, Hiroi N, et al. Differential regulation of Toll like receptor and 
CD14 pathways by retinoids and corticosteroids in human sebocytes. Dermatology. 
2006;213:266. DOI: 10.1159/000095056
[29] Gribbon EM, Cunliffe WJ, Holland KT. Interaction of Propionibacterium acnes with skin 
lipids in vitro. J Gen Microbiol. 1993;139:1745–1751.
[30] Ro BI, Dawson TL. The role of sebaceous gland activity and scalp microfloral metabo-
lism in the etiology of seborrheic dermatitis and dandruff. J Investig Dermatol Symp 
Proc. 2005;10:194–197. DOI: 10.1016/j.cl.2004.03.010
[31] Graham GM, Farrar MD, Cruse Sawyer JE, et al. Proinflammatory cytokine production 
by human keratinocytes stimulated with Propionibacterium acnes and P. acnes GroEL. Br 
J Dermatol. 2004;150:421–428. DOI: 10.1046/j.1365-2133.2004.05762
[32] Nagy I, Pivarcsi A, Kis K, et al. Propionibacterium acnes and lipopolysaccharide 
induce the expression of antimicrobial peptides and proinflammatory cytokines/
chemokines in human sebocytes. Microbes Infect. 2006;8:2195–2205. DOI: 10.1016/j.
micinf.2006.04.001
[33] Jeremy AHT, Holland DB, Roberts SG, et al. Inflammatory events are 
involved in acne lesion initiation. J Invest Dermatol. 2003;121:20–27. DOI: 
10.1046/j.1523-1747.2003.12321
[34] Abdel-Fattah NS, Shaheen MA, Ebrahim AA, El Okda ES. Tissue and blood superoxide 
dismutase activities and malondialdehyde levels in different clinical severities of acne 
vulgaris. Br J Dermatol. 2008;159:1086–1091. DOI: 10.1111/j.1365-2133.2008.08770
[35] Lauermann FT, Almeida HL Jr, Duquia RP, Souza PR, Breunig J de A. Acne scars in 
18-year-old male adolescents: a population-based study of prevalence and associated 
factors. An Bras Dermatol. 2016;91:291–295. DOI: 10.1590/abd1806-4841.20164405
[36] Holland DB, Jeremy AH, Roberts SG, et al. Inflammation in acne scarring: a comparison 
of the responses in lesions from patients prone and not prone to scar. Br J Dermatol. 
2004;150:72–81. DOI: 10.1111/j.1365-2133.2004.05749
[37] Leyden JJ, McGinley KJ, Mills OH, Kligman AM. Propionibacterium levels in patients 
with and without acne vulgaris. J Invest Dermatol. 1975;65:382–384. DOI: 10.1111/1523-
1747.ep12607634
[38] Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflam-
matory cytokine responses. J Immunol. 2002;169:1535–1541. DOI: 10.1159/000087011
[39] Jalian HR, Liu PT, Kanchanapoomi M, et al. All-trans retinoic acid shifts Propionibacterium 
acnes-induced matrix degradation expression profile toward matrix preservation in 
human monocytes. J Invest Dermatol. 2008;128:2777–2782. DOI: 10.1038/jid.2008.155
[40] Nagy I, Pivarcsi A, Koreck A, et al. Distinct strains of Propionibacterium acnes induce 
selective human beta-defensin-2 and interleukin-8 expression in human kera-
tinocytes through toll-like receptors. J Invest Dermatol. 2005;124:931–938. DOI: 
10.1111/j.0022-202X.2005.23705
Acne Vulgaris
http://dx.doi.org/10.5772/65639
33
[41] Sugisaki H, Yamanaka K, Kakeda M, et al. Increased interferon-gamma, interleukin-
12p40 and IL-8 production in Propionibacterium acnes-treated peripheral blood mono-
nuclear cells from patient with acne vulgaris: host response but not bacterial species 
is the determinant factor of the disease. J Dermatol Sci. 2009;55:47–52. DOI: 10.1016/j.
jdermsci.2009.02.015
[42] Chronnell CM, Ghali LR, Ali RS, et al. Human beta defensin-1 and -2 expression in 
human pilosebaceous units: upregulation in acne vulgaris lesions. J Invest Dermatol. 
2001;117:1120–1125. DOI: 10.1046/j.0022-202x.2001.01569
[43] Nakatsuji T, Kao MC, Zhang L, et al. Sebum free fatty acids enhance the innate immune 
defense of human sebocytes by upregulating beta-defensin-2 expression. J Invest 
Dermatol. 2010;130:985–994. DOI: 10.1038/jid.2009.384
[44] Lee DY, Huang CM, Nakatsuji T, et al. Histone H4 is a major component of the antimicrobial 
action of human sebocytes. J Invest Dermatol. 2009;129:2489–2496. DOI: 10.1038/jid.2009.106
[45] Liu PT, Phan J, Tang D, et al. CD209(+) macrophages mediate host defense against 
Propionibacterium acnes. J Immunol. 2008;180:4919–4923. DOI: 10.4049/jimmunol.180.7.4919
[46] Lucky AW, Biro FM, Huster GA, et al. Acne vulgaris in premenarchal girls. An early sign 
of puberty associated with rising levels of dehydroepiandrosterone. Arch Dermatol. 
1994;130:308–314.
[47] Strauss JS, Pochi PE. Effect of cyclic progestin-estrogen therapy on sebum and acne in 
women. JAMA. 1964;190:815–819. DOI: 10.1001/jama.1964.03070220021004
[48] Bowe WP, Joshi SS, Shalita AR. Diet and acne. J Am Acad Dermatol. 2010;63:124–141. 
DOI: 10.1016/j.jaad.2009.07.043
[49] LaRosa CL, Quach KA, Koons K, Kunselman AR, Zhu J, Thiboutot DM, et al. Consumption 
of dairy in teenagers with and without acne. J Am Acad Dermatol. 2016;75:318–322. DOI: 
10.1016/j.jaad.2016.04.030
[50] Capitanio B, Sinagra JL, Bordignon V, et al. Underestimated clinical features of post-
adolescent acne. J Am Acad Dermatol. 2010;63:782–788. DOI: 10.1016/j.jaad.2009.11.021
[51] Jansen T, Plewig G. Acne fulminans. Int J Dermatol. 1998;37:254–257. DOI: 
10.1046/j.1365-4362.1998.00443
[52] Tan BB, Lear JT, Smith AG. Acne fulminans and erythema nodosum during isotreti-
noin therapy responding to dapsone. Clin Exp Dermatol. 1997;22:26–27. DOI: 
10.1046/j.1365-2230.1997.1830600
[53] Wise CA, Gillum JD, Seideman CE, et al. Mutations in CD2BP1 disrupt binding to PTP 
PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol 
Genet. 2002;11:961–969. DOI: 10.1111/j.1600-065X.2008.00747
[54] Friedman SJ, Fox BJ, Albert HL. Solid facial edema as a complication of acne vulgaris: 
treatment with isotretinoin. J Am Acad Dermatol. 1986;15:286–289. DOI: 10.1016/
S0190-9622(86)70168-0
Acne and Acneiform Eruptions34
[55] Jungfer B, Jansen T, Przybilla B, Plewig G. Solid persistent facial edema of acne: suc-
cessful treatment with isotretinoin and ketotifen. Dermatology. 1993;187:34–37. DOI: 
10.1159/000247194
[56] Arbegast KD, Braddock SW, Lamberty LF, Sawka AR. Treatment of infantile cystic acne 
with oral isotretinoin: a case report. Pediatr Dermatol. 1991;8:166–168. DOI: 10.1111/
j.1525-1470.1991.tb00311
[57] Beasley JN. Chemistry and metabolism of benzoyl peroxide and other antiacne drugs. 
Clin Res. 1982;30:698.
[58] Kligman AM, Leyden JJ, Stewart R. New uses for benzoyl peroxide: a broad-spectrum 
antimicrobial agent. Int J Dermatol. 1977;16:413–417.
[59] Patane AM, Pistillo M. Antimicrobial action of benzoyl peroxide. Ann Sclavo. 
1982;24:513–522.
[60] Farmery MR, Jones CE, Eady EA, et al. In vitro activity of azaleic acid, benzoyl perox-
ide and zinc acetata against antibiotic resistant propionibacteria from acne patients. J 
Dermatol Treat. 1994;5:63–65. DOI: 10.3109/09546639409084531
[61] Puschmann M. Clinico-experimental studies on the effect of benzoylperoxide. Hautarzt. 
1982;33:257–265.
[62] Bojar RA, Holland KT, Cunliffe WJ. The in-vitro antimicrobial effects of azelaic acid 
upon Propionibacterium acnes strain P37. J Antimicrob Chemother. 1991;28:843–853. DOI: 
10.1093/jac/28.6.843
[63] Pagnoni A, Kligman AM, Kollias N, et al. Digital flourescence photography can assess the 
suppressive effect of benzoyl peroxide on Propionibacterium acnes. J Am Acad Dermatol. 
1999;41:710–716. DOI: 10.1016/S0190-9622(99)70005-8
[64] Fulton JE, Farzad-Bakshandeh A, Bradley S. Studies on the mechanism of action 
of topical benzoyl peroxide and vitamin A acid in acne vulgaris. J Cutan Pathol. 
1974;1:191–200.
[65] Gloor M, Hummel A, Friedrich HC. Experimentelle untersuchungen zur 
Benzoylperoxidtherapie der acne vulgaris. Z Hautkr. 1975;50:657–663.
[66] Pierard GE, Peirard-Franchimont C, Goffin V. Digital image analysis of microcomedo-
nes. Dermatology. 1995;190:99–103.
[67] Gollnick H, Krautheim A. Topical treatment in acne: current status and future aspects. 
Dermatology. 2003;206:29–36. DOI: 10.1159/000067820
[68] Lassus A. Local treatment of acne. A clinical study and evaluation of the effect of differ-
ent concentrations of benzoyl peroxide gel. Curr Med Res Opin. 1981;7:370–373.
[69] Bojar RA, Cunliffe WJ, Holland KT. The short-term treatment of acne vulgaris with ben-
zoyl peroxide: effects on the surface and follicular cutaneousmicroflora. Br J Dermatol. 
1995;132:204–208.
Acne Vulgaris
http://dx.doi.org/10.5772/65639
35
[70] Del Rosso JQ, Leyden JJ. Status report on antibiotic resistance: implications for the der-
matologist. Dermatol Clin. 2007;25:127–132. DOI: 10.1016/j.det.2007.01.001
[71] Del Rosso JQ, Leyden JJ, Thiboutot D, et al. Antibiotic use in acne vulgaris and rosa-
cea: clinical considerations and resistance issues of significance to dermatologist. Cutis. 
2008;82:5–12.
[72] Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from the global 
alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49:1–38. DOI: 10.1067/
mjd.2003.618
[73] Levy SB. The challenge of antibiotic resistance. Sci Am. 1998;278:46–53.
[74] Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne 
vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis. 
2007;79:9–25.
[75] Ross JL, Snelling AM, Carnegie E, et al. Antibiotic resistant acne: lessons from Europe. Br 
J Dermatol. 2003;148:467–478. DOI: 10.1046/j.1365-2133.2003.05067
[76] Margolis DJ, Bowe WP, Hoffstad O, et al. Antibiotic treatment of acne may be asso-
ciated with upper respiratory tract infections. Arch Dermatol. 2005;141:1132–1136. 
DOI:10.1001/archderm.141.9.1132
[77] Levy RM, Huang EY, Rolling D, et al. Effect of antibiotics on the oropharyngeal flora in 
patients with acne. Arch Dermatol. 2003;139:467–471. DOI: 10.1001/archderm.139.4.467
[78] Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical 
studies. Br J Dermatol. 2005;153:395–403. DOI: 10.1111/j.1365-2133.2005.06614
[79] Cunliffe WJ, Holland KT. Clinical and laboratory studies on treatment with 20% azelaic 
acid cream for acne. Acta Derm Venereol. 1989;143:31–34.
[80] Roberts DL, Marshall R, Marks R. Detection of the action of salicylic acid on the normal 
stratum corneum. Br J Dermatol. 1980;103:191–196. DOI: 10.1111/j.1365-2133.1980.tb06590
[81] Eady EA, Burke BM, Pulling K, et al. The benefit of 2% salicylic acid lotion in acne – a pla-
cebo-controlled study. J Dermatol Treat. 1996;7:93–96. DOI: 10.3109/09546639609089537
[82] Shalita AR. Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the 
treatment of acne vulgaris. Clin Ther. 1989;11:264–267.
[83] Zander E, Weismann S. Treatment of acne vulgaris with salicylic acid pads. Clin Ther. 
1992;14:247–253.
[84] Del Rosso JQ. A status report on the use of subantimicrobial dose doxycycline: a review 
of the biologic and antimicrobial effects of the tetracyclines. Cutis. 2004;74:118–122.
[85] Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria 
clinically relevant? Implications of resistance for acne patients and prescribers. Am J 
Clin Dermatol. 2003;4:813–831. DOI: 10.2165/00128071-200304120-00002
Acne and Acneiform Eruptions36
[86] Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization 
of antibiotic resistant Propionibacterium acnes isolated from acne patients attend-
ing dermatologic clinics in Europe, the USA, Japan and Australia. Br J Dermatol. 
2001;144:339–346.
[87] Leyden JJ. The evolving role of Propionibacterium acnes in acne. Semin Cutan Med Surg. 
2001;20:139–143. DOI: 10.1053/sder.2001.28207
[88] Leyden JJ, Wortzman M, Baldwin EK. Antibiotic resistant Propionibacterium acnes sup-
pressed by benzoyl peroxide 6% cleanser. Cutis. 2008;82:417–421.
[89] Leyden JJ. A review of the use of combination therapies for the treatment of acne vul-
garis. J Am Acad Dermatol. 2003;49:206–210. DOI: 10.1067/S0190-9622(03)01154
[90] Arowojolu A, Gallo M, Lopez L, et al. Combined oral contraceptives for the treatment of 
acne. Cochrane Database Syst Rev. 2009;3:4425. DOI: 10.1002/14651858
[91] Lidegaard O, Lokkegaard E, Svendsen AL, et al. Hormonal contraception and risk of 
venous thromboembolism: national follow-up study. BMJ. 2009;339:2890. DOI: 10.1136/
bmj.b2890
[92] Trenor CC 3rd, Chung RJ, Michelson AD, et al. Hormonal contraception and throm-
botic risk: a multidisciplinary approach. Pediatrics. 2011;127:347–357. DOI: 10.1542/
peds.2010-2221
[93] van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous throm-
botic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results 
of the MEGA case-control study. BMJ. 2009;339:2921. DOI: 10.1136/bmj.b2921
[94] van Wayjen R, van den Ende A. Experience in the long-term treatment of patients with 
hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, met-
abolic and endocrine effects. Exp Clin Endocrinol Diabetes. 1995;103:241–251. DOI: 
10.1055/s-0029-1211357
[95] Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne 
vulgaris and reduces sebum excretion. Br J Dermatol. 1984;111:209–214. DOI: 10.1111/
j.1365-2133.1984.tb04045
[96] Peck GL, Olsen TG, Yoder FW, et al. Prolonged remissions of cystic and con-
globate acne with 13 cis retinoic acid. N Engl J Med. 1979;300:329–333. DOI: 
10.1046/j.1365-2230.2002.01094
[97] Khoo KC, Reik D, Colburn WA. Pharmacokinetics of isotretinoin following a single oral 
dose. J Clin Pharmacol. 1982;22:395–402. DOI: 10.1002/j.1552-4604.1982.tb02692
[98] Colburn WA, Gibson DM, Wiens RE, et al. Food increases the bioavailability of isotreti-
noin. J Clin Pharmacol. 1983;23:534–539. DOI: 10.1002/j.1552-4604.1983.tb01800
[99] Strauss JS, Stranieri AM. Changes in long term sebum production from isotretinoin ther-
apy. J Am Acad Dermatol. 1982;6:751–756. DOI: 10.1016/S0190-9622(82)80055-8
Acne Vulgaris
http://dx.doi.org/10.5772/65639
37
[100] Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a mul-
ticenter dose response study. J Am Acad Dermatol. 1984;10:490–496. DOI: 10.1016/
S0190-9622(84)80100-0
[101] Azoulay L, Oraichi D, Bérard A. Isotretinoin therapy and the incidence of acne 
relapse: a nested case control study. Br J Dermatol. 2007;157:1240–1248. DOI: 
10.1111/j.1365-2133.2007.08250
[102] Bershad S, Rubinstein A, Paterniti JR, et al. Changes in plasma lipids and lipoproteins 
during isotretinoin therapy for acne. N Engl J Med. 1985;313:981–985. DOI: 10.1056/
NEJM198510173131604
[103] Zane LT, Leyden WA, Marqueling AL, et al. A population based analysis of labora-
tory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol. 
2006;142:1016–1022. DOI: 10.1001/archderm.142.8.1016
[104] Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 
1985;313:837–841. DOI: 10.1056/NEJM198510033131401
[105] Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during preg-
nancy. J Am Acad Dermatol. 1992;26:599–606. DOI: 10.1016/0190-9622(92)70088
[106] Lynberg MC, Khoury MJ, Lammer EJ, et al. Sensitivity, specificity, and positive pre-
dictive value of multiple malformations in isotretinoin embryopathy surveillance. 
Teratology. 1990;42:513–519. DOI: 10.1002/tera.1420420508
[107] Lenchik L, Leib ES, Hamdy RC, et al. Executive summary International Society for 
Clinical Densitometry position development conference Denver, Colorado July 20 22, 
2001. J Clin Densitom. 2002;5:1–3. DOI: 10.1385/JCD:7:1:7
[108] Jick SS, Kremers HM, Vasilakis Scaramozza C. Isotretinoin use and risk of depression, 
psychotic symptoms, suicide, and attempted suicide. Arch Dermatol. 2000;136:1231–
1236. DOI: 10.1001/archderm.136.10.1231
[109] Hersom K, Neary MP, Levaux HP, et al. Isotretinoin and antidepressant pharmacother-
apy: a prescription sequence symmetry analysis. J Am Acad Dermatol. 2003;49:424–432. 
DOI: 10.1067/S0190-9622(03)02087-5
[110] Chia CY, Lane W, Chibnall J, et al. Isotretinoin therapy and mood changes in adolescents 
with moderate to severe acne: a cohort study. Arch Dermatol. 2005;141:557–560. DOI: 
10.1001/archderm.141.5.557
[111] Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated 
with isotretinoin: a systematic review. Semin Cutan Med Surg. 2007;26:210–220. DOI: 
10.1016/j.sder.2008.03.005
[112] Azoulay L, Blais L, Koren G, et al. Isotretinoin and the risk of depression in patients with 
acne vulgaris: a case crossover study. J Clin Psychiatry. 2008;69:526–532. DOI: 10.4088/
JCP.v69n0403
Acne and Acneiform Eruptions38
[113] Lowney ED, Witkowski J, Simons HM, et al. Value of comedo extraction in treatment of 
acne vulgaris. JAMA. 1964;189:1000–1002. DOI: 10.1001/jama.1964.03070130020005
[114] Santos MA, Belo VG, Santos G. Effectiveness of photodynamic therapy with topical 5 
aminolevulinic acid and intense pulsed light versus intense pulsed light alone in the 
treatment of acne vulgaris: comparative study. Dermatol Surg. 2005;31:910–915. DOI: 
10.1111/j.1524-4725.2005.31804
[115] Levine RM, Rasmussen JE. Intralesional corticosteroids in the treatment of nodulocystic 
acne. Arch Dermatol. 1983;119:480–481. DOI: 10.1001/archderm.1983.01650300034012
[116] Karimipour DJ, Rittie L, Hammerberg C, et al. Molecular analysis of aggressive micro-
dermabrasion in photoaged skin. Arch Dermatol. 2009;145:1114–1122. DOI: 10.1001/
archdermatol.2009.231
[117] Elman M, Slatkine M, Harth Y. The effective treatment of acne vulgaris by a high inten-
sity, narrow band 405 420 nm light source. J Cosmet Laser Ther. 2003;5:111–117. DOI: 
10.1080/14764170305509
Acne Vulgaris
http://dx.doi.org/10.5772/65639
39

